Clinical trials: Patients With Diabetes.
Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
- Trial name
- REMODEL (NCT04865770)
- Testing
- Semaglutide
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 106 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
Primary objective: Efficacy assessment of the percentage of positive responders patients receiving Lantus plus glucophage association.
- Trial name
- GALATEE (NCT00653302)
- Testing
- Lantus (insulin glargine) + Glucophage (Metformin)
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Sanofi
Foot Ulcer, Diabetic, Infection
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
This is a phase 3, randomized, controlled, blinded, multicenter study conducted in 3 parallel cohorts of diabetic patients with at least 1 infected foot ulcer.
- Trial name
- COACT-1 (NCT02427802)
- Testing
- Gentamicin collagen sponge
- Where
- 86 sites in United States
- Volunteers
- 612 people
- Sponsor
- Innocoll
Diabetes Mellitus Type 2
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment…
- Trial name
- IOOL (NCT00551356)
- Testing
- Insulin lispro mix 25, Glargine
- Where
- Mexico
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Diabetes Mellitus, Type 2, Essential Hypertension
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.
- Trial name
- NCT00328965
- Testing
- Lacidipine
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes
- Trial name
- NCT00147745
- Testing
- Colesevelam, Insulin glargine (Lantus)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo
- Trial name
- NCT02583919
- Testing
- ISIS-GCGRRx- Dose Level 1, ISIS-GCGRRx- Dose Level 2
- Where
- 19 sites in United States
- Volunteers
- 79 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina
The DEAL (Diabetes En America Latina) study was a multicenter, cross-sectional, epidemiological, questionnaire based study carried out between October 2004 and October 2005 in 9 Latin American countries.
- Trial name
- DEAL (NCT01387165)
- Testing
- Treatment
- Volunteers
- 3,592 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
This is a 16-week randomized, double-blind, parallel-group, multi-center, placebo- and active- (metformin 1.5 g) controlled study of tesaglitazar (1 mg) in patients with type 2 diabetes.
- Trial name
- NCT00263965
- Testing
- Tesaglitazar, Metformin, Dietary and lifestyle modification counseling
- Where
- 3 sites in Finland, Italy and 1 more
- Volunteers
- 105 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
This clinical study aims to evaluate the effects of using the "WellCheck" mobile application on blood glucose, blood pressure, and weight among Type 2 diabetes patients in real primary care settings.
- Trial name
- NCT06419816
- Testing
- Physician-managed "WellCheck" use, self-managed "WellCheck" use
- Where
- South Korea
- Volunteers
- 471 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)
The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00087516
- Testing
- Sitagliptin (MK0431), Sitagliptin, Metformin - Rescue
- Volunteers
- 741 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
To Evaluate Clinical Efficacy and Safety of Diabetes-Specific Formula (Nutren Diabetes)
This study has a parallel, non-inferiority design, comparing the 24h AUC of Nutren Diabetes group with Fresubin Diabetes group at 2-4 days since the start of formal intervention.
- Trial name
- NCT05859165
- Testing
- Nutren Diabetes, Fresubin Diabetes
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Société des Produits Nestlé (SPN)
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Primary Objective: To compare the effect of sotagliflozin to placebo on the total occurrences of cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (HF) in hemodynamically…
- Trial name
- NCT03521934
- Testing
- Sotagliflozin
- Where
- 466 sites in United States, Argentina and 30 more
- Volunteers
- 1,222 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 1
Study of LY2409021 in Participants With Type 1 Diabetes
This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or placebo (an inactive medicine) taken as up to 3 capsules by mouth.
- Trial name
- NCT01640834
- Testing
- LY2409021, Glucagon
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of Teneligliptin in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration and to evaluate the safety and efficacy of Teneligliptin…
- Trial name
- NCT02081599
- Testing
- Teneli (Teneligliptin), Insulin
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Primary Objective: The primary objective of this study was to assess the dose-response relationship of SAR425899 versus placebo in terms of glycemic control as measured by the change in glycosylated hemoglobin (HbA1c).
- Trial name
- NCT02973321
- Testing
- SAR425899, Liraglutide, Metformin
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
Primary Objective: To demonstrate the superiority of sotagliflozin dose 1 versus placebo on hemoglobin A1c (HbA1c) reduction in Chinese patients with type 2 diabetes (T2D) who have inadequate glycemic control on diet and…
- Trial name
- NCT03760965
- Testing
- sotagliflozin (SAR439954)
- Where
- 29 sites in China
- Volunteers
- 276 people
- Sponsor
- Sanofi
Type 1 Diabetes
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
This is a single-centre, randomised, double-blind, 4-way crossover, 4-treatment, euglycaemic clamp study in subjects with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT04501107
- Testing
- Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1), Administration of Ready-to-use BioChaperone insulin lispro (IMP2), Administration of US-approved Humalog® (IMP3)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Adocia
Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes
- Trial name
- NCT00874809
- Testing
- CGMS with an insulin pump using rapid acting insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diabetes Care Center